The Union Health Ministry has reiterated that stem cell therapy for Autism Spectrum Disorder (ASD) can only be offered as part of approved clinical trials, not as routine or commercial treatment. This follows a landmark Supreme Court judgment in January 2026 that examined the issue. The advisory reinforces existing regulations under the Clinical Establishments Act, 2010, and the National Guidelines for Stem Cell Research, 2017.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Advisory Date: September 16, 2026
- ›SC Judgment Date: January 30, 2026
- ›Target this Data: 18 adult and 14 paediatric approved indications for stem cell therapy.
- ›Target this Nodal Body: Health Ministry (advisory) and ICMR (evidence review).
- ›Target this Legal Point: Clinical Establishments (Registration and Regulation) Act, 2010, Sections 32 and 40.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.